German Court Blocks Merck’s Subcutaneous Keytruda Over Patent Dispute with Halozyme
A German court has granted Halozyme a preliminary injunction blocking Merck & Co. from distributing the subcutaneous formulation of Keytruda (Keytruda SC) in Germany.
The Munich Regional Court ruled that Merck’s Keytruda SC infringes Halozyme’s MDASE-related patents in Europe.
The injunction applies only to the subcutaneous version of Keytruda, not the intravenous formulation.
Halozyme is also seeking to invalidate Merck’s Keytruda SC patent in the German Federal Patent Court and has filed a related lawsuit in U.S. federal court to block distribution there.
Merck has initiated proceedings in Germany to nullify Halozyme’s patent at issue; that case remains pending.